Child Overweight, Obesity Linked to Increased Asthma Risk

November 26, 2018

In absence of overweight and obesity, 10 percent of all pediatric asthma cases would be avoided

Several Asthma, Allergy Groups Express "Deep Concern" Over Primatene MIST Approval

By November 12, 2018

Primatene MIST was approved earlier this month for over-the-counter (OTC) use for the temporary relief of mild symptoms of intermittent asthma (eg, wheezing, tightness of chest, shortness of breath) in patients aged ≥12 years.

Millions of ER Visits for Asthma Due to Air Pollution

October 26, 2018

9 to 23 and 5 to 10 million annual asthma ER visits attributed to ozone and PM2.5 globally

Dupixent Approved as Add-On Maintenance Tx for Moderate-to-Severe Asthma

By October 22, 2018

In the asthma clinical trials, the most common adverse reactions were injection site reactions, oropharyngeal pain, and eosinophilia.

Xolair Prefilled Syringe Formulation Gets FDA Approval

By October 01, 2018

The PFS formulation eliminates the need to reconstitute the solution before administration.

Eosinophilic Asthma Treatment: Biologic Agents Compared

By September 21, 2018

PubMed was searched to obtain data on the relative efficacies of benralizumab, dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab.

Benralizumab Efficacy Maintained in Long-Term Severe Eosinophilic Asthma Study

By September 19, 2018

Results from the extension trial showed a similar safety and tolerability profile for Fasenra as that seen in SIROCCO and CALIMA.

Addition of High-Dose Guaifenesin Benefits Patient With Chronic Respiratory Conditions

By September 13, 2018

According to the report, the patient complained of a non-productive cough, accumulation of mucus, and post-nasal drip and requested a thorough assessment of her medical conditions.

Anti-IL5 Treatments Compared in Patients With Severe Eosinophilic Asthma

By September 11, 2018

Currently, 3 anti-interleukin (IL)5 pathway-directed treatments (benralizumab, mepolizumab, reslizumab) have been approved by the Food and Drug Administration for the treatment of severe asthma with an eosinophilic phenotype

Tezepelumab Gets Breakthrough Therapy Designation for Severe Asthma

By September 07, 2018

The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.

Biologic Therapy Selection for Severe Asthma: Factors to Consider

By August 15, 2018

The authors write that once severe asthma is diagnosed, clinicians should determine asthma endotype (Type2-high or Type2-low) to help choose the best therapy for the patient.

Hailie Sensor Gets FDA Clearance for Additional Asthma Inhalers

By July 27, 2018

The Hailie sensor attaches to the asthma or chronic obstructive pulmonary disease (COPD) inhaler to monitor and help patient adherence.

Asthma Control and Atrial Fibrillation Risk: Is There a Link?

July 13, 2018

Dose-response association seen between levels of asthma control and risk of atrial fibrillation

Patient Engagement in Asthma Treatment Plans May Improve Quality of Life

July 02, 2018

In older adults with asthma, decision making scores positively correlated with QoL scores

Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids

By April 12, 2018

Iatrogenic steroid-induced psychosis is a rare side effect of glucocorticoid therapy which is mostly seen in adults, although it has been reported in children and adolescents.

Smartinhaler Sensor for Symbicort Will Be Available Over-the-Counter

By March 27, 2018

The Smartinhaler sensor is a device installed onto a patient's inhaler to monitor and promote asthma and COPD medication adherence.

SCIT May Cut Long-Term Asthma Med Use in Pediatric Allergic Asthma

By March 26, 2018

Allergen avoidance, drug therapy, and allergen immunotherapy are all treatment options for allergic asthma.

Dupilumab Under FDA Review for Moderate-to-Severe Asthma

By March 02, 2018

Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signaling proteins (cytokines) that contribute to Type 2 inflammation in moderate-to-severe asthma.

Treatment Options for Patients With Severe Asthma

By February 16, 2018

Severe asthma is a challenging condition. Available therapeutic options for severe asthma include tiotropium, omalizumab, interleukin-5 targeted therapies, macrolide antibiotics, and bronchial thermoplasty.

Breath-Actuated Qvar RediHaler Available for Asthma Maintenance Treatment

By February 12, 2018

Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is a breath-actuated inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in people 4 years of age and older.

Asthma Guideline Adherence, Agreement Assessed Among PCPs, Specialists

By February 09, 2018

To examine real-world clinician adherence to these guidelines, as well as agreement and self-efficacy, researchers analyzed data from the 2012 National Asthma Survey of Physicians.

Asthma Treatment Aerospan Has Been Discontinued

By January 29, 2018

Both the 60- and 120-actuation sizes have been discontinued.

CDC: Certain Occupations Linked to Elevated Asthma Mortality

By January 19, 2018

The food, beverage and tobacco manufacturing industry (1.82) had the highest elevated asthma PMRs for men. Among women, the social assistance industry (1.35) and community social services occupations (1.46) had the highest elevated asthma PMRs.

Fasenra Approved for Severe Eosinophilic Asthma

By November 15, 2017

Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Does Inhaled Corticosteroid Use Up the Risk of Fracture in Children?

November 14, 2017

Inhaled corticosteroids are not associated with increased odds of fracture in the pediatric asthma population

Dupilumab Beneficial for Patients with Severe Steroid-Dependent Asthma

By October 31, 2017

Consistent reductions in asthma attacks and improvements in lung function across a broad population of uncontrolled asthma patients.

Asthma Drug Linked to Neuropsychiatric Adverse Events

By September 21, 2017

Results found that overall depression was the most commonly reported adverse event in the VigiBase group while headaches were the most frequent adverse event reported for the Dutch database.

Xolair Re-Treatment Still Effective in Chronic Spontaneous Urticaria

By September 19, 2017

Among the re-treated patients, almost 90% achieved symptom control (UAS7 ≤6) within 3 months. During both dosing periods, Xolair 150mg and 300mg were well-tolerated

Dupilumab Beneficial in Patients with Uncontrolled, Persistent Asthma

By September 12, 2017

Results found that at 52 weeks severe asthma attacks were reduced by 46% in the overall population for the 300mg dose group and by 60% and 67% among those patients with ≥150 eosinophilic cells/microliter or greater and ≥300 eosinophilic cells/microliter, respectively (P<0.001).

FDA Approves Inhaler Monitoring Device for Symbicort

By September 06, 2017

The SmartTouch for Symbicort is a monitoring device that is installed onto the patient's inhaler to track and improve medication adherence.